Overview

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Medical Appliances, Egypt) and Trajenta 5 mg tablets(Boehringer Ingelheim International GmbH, Germany) after a single oral dose administration of each to healthy adults under fasting conditions

Phase:

Phase 1

Details

Lead Sponsor:

Genuine Research Center, Egypt

Collaborators:

Eva Pharma
EVA pharma, Egypt

Treatments:

Linagliptin